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Heat shock protein 10 (Hsp10) and heat shock protein
60 (Hsp60) were originally described as essential mito-
chondrial proteins involved in protein folding. How-
ever, both proteins have also been shown to have a num-
ber of extracellular immunomodulatory activities. Here
we show that purified recombinant human Hsp10 incu-
bated with cells in vitro reduced lipopolysaccharide
(LPS)-induced nuclear factor-B activation and secre-
tion of several inflammatory mediators from RAW264.7
cells, murinemacrophages, and human peripheral blood
mononuclear cells. Induction of tolerance by contami-
nating LPS was formally excluded as being responsible
for Hsp10 activity. Treatment of mice with Hsp10 before
endotoxin challenge resulted in the reduction of serum
tumor necrosis factor- and RANTES (regulated upon
activation, normal T cell expressed and secreted) levels
and an elevation of serum interleukin-10 levels. Hsp10
treatment also delayed mortality in a murine graft-ver-
sus-host disease model, where gut-derived LPS contrib-
utes to pathology. We were unable to confirm previous
reports that Hsp10 has tumor growth factor properties
and suggest that Hsp10 exerts anti-inflammatory activ-
ity by inhibiting Toll-like receptor signaling possibly by
interacting with extracellular Hsp60.
Mammalian heat shock protein 10 (Hsp10)1 and heat shock
protein 60 (Hsp60), also known as chaperonins 10 and 60, are
mitochondrial proteins involved in protein folding. In the mi-
tochondria Hsp10 forms a heptameric lid, which binds to a
double-ring toroidal structure comprising seven Hsp60 sub-
units per ring (1–3). In addition to its mitochondrial role,
Hsp60 has also been found at the cell surface (4–10) and in the
extracellular fluid (11, 12) and has been associated with a
variety of immunomodulatory activities (13, 14). Heat shock
proteins (Hsps) exported to the plasma membrane or released
from dying cells are believed to be a source of “danger” signals,
informing the innate and adaptive immune systems of tissue
damage induced by various insults including infection, injury,
toxins, heat, and/or cellular stress (13, 15, 16). Elevated expres-
sion of Hsp60 has been associated with a number of inflamma-
tory disorders (11, 17, 18), and a correlation has been found
between elevated serum Hsp60 and increased levels of the
pro-inflammatory cytokine, TNF-, psychological distress, low
socioeconomic status, and social isolation (12).
Toll-like receptors (TLRs) have emerged as central players in
inflammation and innate immunity and are triggered by a
variety of pathogen- and host-derived factors, thereby detecting
both infection and tissue damage. Host Hsp60, Hsp70, and
Gp96 have been reported to be agonists for TLR2 and TLR4 (14,
16, 19), and these receptors are also triggered by lipoproteins
and lipopolysaccharides (LPS), respectively. How cell surface
or serum Hsp60 might interact with TLR4 signaling remains
unclear. Hsps have been localized to the multicomponent TLR4
receptor complex and may influence signal transduction (20).
Alternatively, Hsp60 may interact with other components of
the multifaceted mammalian LPS recognition system leading
to modulation of LPS-mediated signaling (7, 21). Recent evi-
dence has, however, cast doubt on the ability of Hsp60 and
Hsp70 to induce pro-inflammatory responses by themselves,
since Hsp preparations substantially free of LPS and lipopro-
tein contaminations failed to stimulate macrophages (22, 23).
Nevertheless, anti-Hsp60 antibodies can inhibit Hsp60-in-
duced pro-inflammatory cytokine production by macrophages
(24, 25), perhaps suggesting that Hsp60 may potentiate TLR4
signaling by low levels of LPS rather than being responsible for
TLR-mediated cellular activation in isolation (13).
TLR engagement primarily results in activation of the nu-
clear factor-B (NF-B) (16), although a series of other path-
ways are also triggered, including interferon regulatory factor
3, p38 mitogen-activated kinase, c-Jun-N-terminal kinase, and
extracellular signal related kinase pathways (14, 21, 26). The
patterns of gene expression induced by ligation of the different
TLRs are distinct but often overlap. For instance a large pro-
portion of the genes up-regulated by double-stranded RNA via
TLR3 ligation are also up-regulated by LPS via TLR4 ligation
(26). TLRs are expressed on cells of the monocyte lineage in-
cluding macrophages and dendritic cells, and their ligation
usually leads to secretion of a number of pro-inflammatory
cytokines and chemokines; for instance LPS binding to macro-
phage TLR4 results in TNF-, IL-6, and RANTES secretion
(14, 27). Excessive inflammation or uncurtailed immune re-
sponses can be detrimental to the host; hence, a number of
negative feedback systems have evolved to dampen secretion of
pro-inflammatory mediators (28, 29). These include IL-10, an
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important immunoregulatory cytokine that is involved in limi-
tation of inflammatory responses and induction of immune
tolerance (29–31). Many diseases are also associated with ex-
cessive or chronic inflammation; hence, pro- and anti-inflam-
matory pathways have become the subject of extensive re-
search with a view to developing novel therapeutic anti-
inflammatory and immunomodulatory interventions (28, 29,
31–34).
Hsp10 was originally identified as a factor present in sera
during early pregnancy and has shown immunosuppressive
activity in experimental autoimmune encephalomyelitis, de-
layed type hypersensitivity, and allograft rejection models
(35, 36). We demonstrate here that recombinant Hsp10 sub-
stantially free of endotoxin inhibited LPS-induced activation
of NF-B, reduced LPS-induced TNF-, RANTES, and IL-6
secretion, and enhanced IL-10 production. Anti-Hsp60 anti-
bodies prevented and mimicked Hsp10 inhibitory activity,
suggesting that Hsp10 may inhibit pro-inflammatory re-
sponses by interacting with extracellular Hsp60. We were
unable to confirm earlier reports that Hsp10 has tumor
growth factor properties (37–41).
EXPERIMENTAL PROCEDURES
RAW264-HIV-LTR-LUC Bioassay—RAW264-HIV-LTR-LUC cells
(42) (a kind gift from Prof. D. Hume, University of Queensland) were
cultured (43) in the presence of G418 (200 g/ml) for 1 week after
recovery from liquid nitrogen and grown as suspension cultures in
25-cm3 flasks (Greiner Labortechnik, Frickenhausen, Germany).
RAW264-HIV-LTR-LUC cells were disaggregated by repeated pipetting
and plated at 2.5  105 cells/well in 24-well plates and incubated
overnight (37 °C and 5% CO2). LPS from Escherichia coli (Sigma
L-6529; strain 055:B5, Sigma) was dissolved in sterile distilled water
and stored at 4 °C at 1 mg/ml in glass vials. Immediately before use the
solution was vigorously vortexed before aliquots were taken. The cells
were incubated with LPS, Hsp10, or control buffers for 2 h followed by
the addition of stimulating LPS at the indicated concentrations. After a
further 2-h incubation the adherent cells were processed for the luciferase
assay (Luciferase Assay System, Promega, Madison, WI). Luciferase
activity was read for 15 s on a Turner Designs Luminometer TD 20/20.
Production and Purification of Hsp10—Recombinant human Hsp10
(GenBankTM accession number X75821) was produced in E. coli essen-
tially as described by Ryan et al. (44). In addition, the material that did
not bind Macro-Prep High Q (Bio-Rad) was further purified by S-
Sepharose and then gel filtration (Superdex 200, Amersham Bio-
sciences). Purified Hsp10 in a 50 mM Tris-HCl (pH 7.6) and 150 mM
NaCl buffer was filtered through an Acrodisc filter system with a
0.2-mmMustang E membrane according to the manufacturer’s instruc-
tions (Pall Corp., Ann Arbor, MI; catalog number MSTG5E3) to remove
residual endotoxins and was stored at 70 °C. The purity of Hsp10 was
determined to be 97% by SDS-PAGE. Aliquots were thawed once
before use. All batches of Hsp10 showed the same molar activity as
GroES in GroEL-mediated rhodanese refolding assays (45) (data not
shown). LPS contamination of Hsp10 was determined by the Limulus
Amebocyte Lysate assay (BioWhittaker, Walkersville, MD) to be 1
endotoxin units/mg purified Hsp10 protein.
Trypsin Treatment of Hsp10—2.5% trypsin (Gibco) was filtered
through an Acrodisc filter as above twice and added at 40 g/ml to
Hsp10 (at 2–3 mg/ml). After incubation at 37 °C overnight the trypsin/
Hsp10 solution was heated to 90 °C for 15 min to destroy trypsin
activity and cooled before addition to the bioassays. After trypsin treat-
ment no Hsp10 could be detected by SDS-PAGE and Western blotting,
and the material was inactive in the rhodanese refolding assay (data
not shown).
Tumor Cell Lines—K562 (human erythroleukemia), Mono Mac 6
(human monocytic line), U937 (human histiocytic lymphoma), P815
(mouse mastocytoma), EL4 (mouse T cell lymphoma), Jurkat (human T
cell leukemia), RAW 264.7 (ATCC TIB 71, mouse macrophage), L929
(mouse fibrosarcoma), B16 (mouse melanoma), HeLa (human cervical
carcinoma), and MCA-2 (mouse fibrosarcoma) cell lines were shown to
be mycoplasma negative (46). Cells were grown in medium including
RPMI 1640 (or Dulbecco’s modified Eagle’s medium for MCA-2 cells)
(Gibco), 10% fetal bovine serum (Gibco), 2 mM glutamine (Sigma), 10
mM HEPES (Sigma), 100 g/ml streptomycin, and 100 IU/ml penicillin
(CSL Ltd, Melbourne, Australia).
In Vitro Growth Assay—Cells were seeded into 96-well flat bottom
plates at 4  103 cells/well at the indicated concentration of Hsp10.
After 2–4 days in culture and before cells reached confluence, adherent
cells were fixed in 100% methanol, and protein was determined using
the sulforhodamine B assay (47). Non-adherent cells were counted
under microscope hemocytometer in the presence of trypan blue to
indicate non-viable cells. Anti-Hsp10 antibody was raised in rabbits by
immunizing four times with Hsp10 (100 g) emulsified in complete
Freund’s adjuvant. IgG was purified from serum using protein
A-Sepharose (Sigma) followed by affinity column chromatography using
Hsp10 coupled to Affi-Gel 10 (Bio-Rad). Purified anti-Hsp10 IgG at 2.74
mg/ml had an end point titer of 1 in 2 million by enzyme-linked immu-
nosorbent assay (ELISA). IgG purified from naive rabbit serum was
used as a control and had no detectable reactivity to Hsp10 by ELISA.
In Vivo Tumor Growth—B16 cells, Lewis lung, or MCA-2 tumors
were inoculated subcutaneously (105 cells per site, 2 sites per mouse, 5
mice per group) into the shaved backs of C57BL/6 or CBA mice (for
MCA-2). Doses of 10 or 100 g/mouse of Hsp10 were given subcutane-
ously daily for 10 days beginning on the day of tumor inoculation.
Control groups received the same volume of 50 mM Tris/saline buffer.
Tumor growth was monitored as described previously (48). Mice bear-
ing tumors greater than 100 mm2 were euthanized.
RAW264.7 IL-6 and RANTES Assays—RAW264.7 cells were seeded
at 2.5  105 cells/well in 24-well plates and cultured overnight (37 °C
and 5% CO2). Hsp10 or buffer was added to cells in triplicate for 2 h
followed by the addition of LPS (1 ng/ml). After 6 h, supernatants were
collected and analyzed for RANTES and IL-6 using specific ELISA-
paired antibody kits (R & D Systems, Minneapolis, MN). ELISA stand-
ards and samples were run in duplicate, and the sensitivity of the
assays was 31 and 15.6 pg/ml for RANTES and IL-6, respectively. The
optical density (450 nm) of each sample was determined using a micro-
plate reader (Tecan Sunrise, Austria, with Magellan V3.11 software).
Cytokine Production from Splenocytes and Macrophages Derived
from Hsp10-treated Animals—C57BL/6 (H-2b, Ly-5.2) mice were pur-
chased from the Australian Research Centre (Perth, Western Australia,
Australia) and C57BL/6 IL-10/mice (H-2b, Ly-5.2) were supplied by
the Australian National University (Canberra, Australia). The culture
medium used throughout was 10% fetal bovine serum/Iscove’s modified
Dulbecco’s medium (JRH Biosciences, Lenexa, KS) supplemented with
50 units/ml penicillin, 50 g/ml streptomycin, 2 mM L-glutamine, 1 mM
sodium pyruvate, 0.1 mM nonessential amino acid, 0.02 mM -mercap-
toethanol, and 10 mM HEPES, and cells were cultured at pH 7.75,
37 °C, and 5% CO2. C57BL/6 mice (n  3 per group) were treated with
subcutaneous injections of Hsp10 (100 g) or diluent buffer daily for 5
days, and peritoneal macrophages were harvested on the sixth day by
peritoneal lavage and pooled from individual animals within the treat-
ment group. Cells were plated in triplicate at 2  105/well in the
presence of LPS (1 g/ml). Culture supernatants were collected at 5 h,
and levels of TNF- were assessed by ELISA. Results were normalized
to production per 105 macrophages based on CD11b staining by fluo-
rescence-activated cell sorter analysis of input cells.
For IL-10 determination, splenocytes were harvested from the same
animals and pooled as above and cultured in triplicate at 5  105
cells/well in the absence (not shown) or presence of LPS (10 g/ml).
Culture supernatants were collected at 48 h, and levels of IL-10 were
determined by ELISA.
For T cell-derived cytokine production, spleen-derived nylon wool-
purified T cells (49) (2  106 CD3-positive cells/24 well) from Hsp10-
treated or control-treated C57BL/6 mice were stimulated in vitro with
irradiated (2000 rads) allogeneic B6D2F1 splenocytes (3  106/24
wells). After 7 days cells were collected and plated in triplicate (5  105
CD3-positive cells/96-well) and re-stimulated with plate-bound antibod-
ies to CD3 and CD28 (from hybridomas 2C11 and N37.51), which were
prepared by incubating the antibodies (10 g/ml) overnight at 4 °C in
96-well flat bottom plates followed by washing twice with phosphate-
buffered saline (49). Culture supernatants were harvested at 24 h, and
concentrations of cytokines were determined by ELISA.
The monoclonal antibody pairs used in the TNF-, interferon- (IFN-
), IL-10, and IL-4 ELISA assays were used at concentrations recom-
mended by the supplier (Pharmingen). Supernatants were diluted in
culture medium 1:1 for IL-4, IL-10, and TNF- and 1:50 for IFN-.
Cytokines were captured by the capture antibody and detected by the
direct biotin-labeled detection antibody. Streptavidin-labeled horserad-
ish peroxidase (Kirkegaard and Perry laboratories, Gaithersburg, MD)
and substrate (Sigmafast OPD, Sigma) was then used to measure
immobilized biotin. Plates were read at 492 nm using the Spectraflour
Plus microplate reader (Tecan). Recombinant cytokines (Pharmingen)
were used as standards for ELISA assays. Standards were run in
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duplicate, and the sensitivity of the assays was 0.063 units/ml for IFN-
and 15 pg/ml for IL-10, IL-4, and TNF-.
Human Peripheral Blood Mononuclear Cell (PBMC) TNF- and IL-6
Assays—Human PBMC were isolated from heparinized blood of healthy
volunteers by buoyant density gradient centrifugation on Ficoll-Paque
Plus (Amersham Biosciences). PBMC were dispensed at 106 viable
cells/ml in 200 l in 96-well tissue culture plates (Greiner Bio-One,
Kremsmuenster, Austria). Hsp10 was then added, and plates were
incubated for 1 h followed by LPS addition and a further 20-h incuba-
tion at 37 °C and 5% CO2, after which supernatants were collected, and
duplicate samples were analyzed for TNF- and IL-6 levels (Duoset
ELISA kits, R & D Systems). The sensitivity of these assays was 31
pg/ml TNF- and 9 pg/ml IL-6.
Mouse Serum TNF-, RANTES, and IL-10 Assays after LPS Injec-
tion—Female BALB/c mice aged 6–8 weeks were given 100 g of
Hsp10/mouse with or without LPS at 10 g/mouse. Hsp10 was admin-
istered intravenously 30 min before the intravenous injection of LPS
diluted in phosphate-buffered saline (the final volume was 100 l; see
above for preparation and storage of LPS stock solution). The mice were
sacrificed, and blood was collected via cardiac puncture 1.5 h after LPS
challenge. Blood was collected into 0.8-ml clotting accelerator tubes
(MiniCollect, Interpath) and serum-stored at 4 °C for analysis of
TNF-, RANTES, and IL-10 using commercially available ELISA kits
(R & D Systems, BD Biosciences Pharmingen).
Bone Marrow Transplantation and Graft Verses Host Disease—Fe-
male 8–14-week-old C57BL/6 (B6, H-2b, Ly-5.2), B6 Ptprca Ly-5a (H-
2b, Ly-5.1), and B6D2F1 (H-2b/d, Ly-5.2) (50) mice were purchased
from the Australian Research Centre (Perth, Western Australia).
Hsp10 (100 g per animal) or control diluent buffer was injected sub-
cutaneously daily for 5 days into donor and recipient animals before
transplant. Mice were housed in sterilized microisolator cages and
received acidified autoclaved water (pH 2.5) and normal food for the
first 2 weeks post-transplantation. Mice were transplanted according to
a standard protocol described previously (51–53). Briefly, on day 1
B6D2F1 mice received 1300 centigray total body irradiation (137Cs
source at 108 centigray/min) split into two doses separated by 3 h to
minimize gastrointestinal toxicity. Donor bone marrow (5  106) and
donor nylon wool purified splenic T cells (2  106) were resuspended in
0.25 ml of Leibovitz’s L-15 media (Invitrogen) and were injected intra-
venously into each recipient. Survival was monitored daily, and graft-
versus-host disease (GVHD) clinical scores were measured weekly. The
degree of systemic GVHD was assessed by a scoring system, which
sums changes in five clinical parameters, which are weight loss, posture
(hunching), activity, fur texture, and skin integrity (maximum index 
10) (51–54). Individual mice were ear-tagged and graded from 0 to 2 for
each criterion without knowledge of treatment group. Animals with
severe clinical GVHD (scores 6) were sacrificed according to ethical
guidelines, and the day of death was deemed to be the following day.
Inhibition of Hsp10 Activity with Anti-Hsp60 Serum—RAW264-HIV-
LTR-LUC cells were plated and incubated overnight as above. The
medium was replaced, and goat polyclonal anti-Hsp60 serum (1/1000
dilution) (Stressgen, Victoria, Canada) or the same dilution of normal
goat serum was added for 1 h. Hsp10 or buffer was then added for a
further 2 h followed by buffer or LPS at the indicated concentrations,
and luciferase activity was measured 2 h later.
Statistical Analysis—Statistical analysis (univariate analysis of vari-
ance: ANOVA, Student’s t test, or log rank statistic) was performed
using SPSS for Windows 11.5.0 (SPSS Inc.).
RESULTS
The Endotoxin Content of Purified Recombinant Hsp10 Was
Below Detection—The Hsp literature has been complicated by
the potential presence of contaminating endotoxin in recombi-
nant Hsp preparations (22, 23). To illustrate that recombinant
Hsp10 preparations were substantially free of endotoxin, two
highly sensitive bioassays were used. The RAW264-HIV-LTR-
LUC cell line is a mouse macrophage cell line (RAW264.7)
stably expressing a luciferase reporter gene under the control
of an HIV long terminal repeat promoter, which is highly and
rapidly responsive to NF-B stimulation. These cells provide a
sensitive bioassay for the presence of LPS (42, 55), and in our
hands the assay was able to detect 5–10 pg/ml E. coli LPS (Fig.
1A, light bars). Importantly, Hsp10 (100 g/ml), and the dilu-
ent Tris/NaCl buffer failed to generate luciferase activity above
background (Fig. 1A, Hsp10 and Buffer (dark bars)).
The second endotoxin bioassay utilized TNF- production by
human PBMC and was able to detect 40 pg/ml LPS (Fig. 1B).
Using this assay neither Hsp10 (100 g/ml) nor the diluent
buffer induced detectable TNF- secretion in PBMC from three
donors (Fig. 1B). Thus, the Hsp10 material used in this study
contained levels of endotoxin below the level of detection of two
highly sensitive bioassays and failed to stimulate either
RAW264-HIV-LTR-LUC cells or PBMC when used at 100 g/ml.
Because Figs. 3 and 5 will illustrate that Hsp10 inhibits LPS
stimulation of RAW264-HIV-LTR-LUC cells and PBMC, re-
spectively, it was important to establish that Hsp10 did not
inhibit the ability to detect potential LPS contamination in
these bioassays. Trypsin treatment of Hsp10 resulted in the
degradation of Hsp10 to levels undetectable by SDS-PAGE and
Western blotting and the rhodanese refolding assay (data not
shown). Trypsin treatment included a final heating to 90 °C for
15 min to destroy trypsin activity before the use of the material
in the bioassays (see ”Materials andMethods“). This heat treat-
ment did not affect LPS activity (Trypsin LPS, Fig. 3B). Im-
FIG. 1. Lack of detectable endotoxin contamination in preparations of recombinant Hsp10. A, RAW264-HIV-LTR-LUC cells were
stimulated for 2 h with a range of LPS concentrations (n  3 replicates per concentration, light bars), the Tris/NaCl buffer used to dissolve the
Hsp10 (Buffer, n  5), Hsp10 (Hsp10, n  5), and trypsin/heat-treated Hsp10 (Trypsin/Hsp10, n  4). Results are expressed as relative light units
of luciferase activity. B, human PBMC from three different donors (dark gray, donor 1; light gray, donor 2; black bars, donor 3) were stimulated
with a range of LPS concentrations, diluent buffer (Buffer), Hsp10 (Hsp10), and trypsin/heat-treated Hsp10 (Trypsin/Hsp10). Supernatants were
removed after 20 h and analyzed for levels of TNF- by ELISA. The limit of detection of this assay was 31 pg/ml TNF-.
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portantly, trypsin-treated Hsp10 failed to stimulate RAW264-
HIV-LTR-LUC cells or PBMC (Fig. 1, A and B, Trypsin/Hsp10),
illustrating that Hsp10 did not mask potential LPS
contamination.
Hsp10 and Anti-Hsp10 Antibodies and the Growth of Tumor
Cells in Vitro and in Vivo—Monoclonal antibodies to Hsp10
have been reported to inhibit the growth of mouse B16 mela-
noma and MCA-2 fibrosarcoma cells in vitro (40) and in vivo
(41), leading to the conclusion that Hsp10 has growth factor
properties. Using a high titer, affinity-purified polyclonal anti-
Hsp10 antibody at concentrations up to 500 g/ml, we were
unable to influence the growth of B16 or MCA-2 in vitro when
compared with purified control antibodies used at the same
dose (Fig. 2A). The results from the previous studies may be
explained by the use of ascites-derived anti-Hsp10 monoclonal
antibodies, whereas the control antibodies were derived from
tissue culture supernatants (40, 41). Ascites fluid-derived ma-
terial frequently contains growth-suppressing inflammatory
cytokines, which are not usually present in tissue culture-
derived antibody preparations (56).
To further investigate potential growth factor activity of
Hsp10, the growth of a panel of tumor cells was tested in vivo
and in vitro in the presence of purified recombinant Hsp10.
Hsp10 administered at 10 g (data not shown) or 100 g per
day for 10 days did not influence the growth of B16, MCA-2, or
Lewis Lung tumors in vivo (Fig. 1C) (in our hands the MCA-2
tumor spontaneously regressed and was no longer visible on
day 12). Furthermore, Hsp10 did not enhance the growth of a
large panel of tumor cell lines including B16 and MCA-2 in
vitro (Fig. 1, C and D). Taken together with the antibody data,
these experiments do not support a role for Hsp10 as a tumor
growth factor.
Hsp10 Inhibited LPS Signaling in RAW264-HIV-LTR-LUC
Indicator Cells—During the endotoxin testing experiments
(Fig. 1), it emerged that Hsp10 was able to inhibit LPS-
mediated activation of the RAW264-HIV-LTR-LUC cell line.
The HIV long terminal repeat promoter present in these cells
is highly and rapidly responsive to NF-B stimulation, and
these cells provide a sensitive bioassay for analysis of TLR4
signaling pathways in macrophages stimulated with
FIG. 2. Anti-Hsp10 antibodies did not inhibit and Hsp10 did not enhance growth of tumor lines in vitro and in vivo. A, anti-Hsp
antibodies did not influence tumor cell growth in vitro. B16 and MCA-2 cells were seeded into 96-well plates in triplicate in the presence of
the indicated concentrations of affinity purified rabbit anti-Hsp10 immunoglobulin (Anti-Hsp10), control rabbit immunoglobulin (Rabbit Ig),
or buffer. Parallel plates were fixed 4 h after seeding (Day 0) and on days 2 and 5, and cell numbers were assessed using the sulforhodamine
B protein stain. B, Hsp10 did not influence tumor growth in vivo. Mice (n  5 per group) were inoculated with B16, Lewis Lung, or MCA-2
tumors subcutaneously (2 tumors per mouse) and given 100 g of Hsp10 (black squares) or the same volume of buffer (white squares) daily for
10 days starting on the day of tumor inoculation. Tumor size was determined at the indicated times. C and D, Hsp10 did not enhance tumor
growth in vitro. Tumor cell lines were seeded into 96-well plates and cultured for 2–3 days (before reaching confluence) in the presence of the
indicated concentration of Hsp10. Cell numbers were then assessed using the sulforhodamine B protein stain for adherent cells (C) or trypan
blue exclusion (D) for non-adherent cells (dark bars represent non-viable cell counts, and light bars represent viable cell counts, which exclude
the dye). Data represent the mean of triplicate wells  S.D.
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bacterial LPS (42, 55). To avoid the use of supra-physiological
levels of LPS (23), a titration range for LPS concentration
was established that represented 80, 50, and 20% of maxi-
mal LPS-stimulated luciferase activity; these were 5, 1, and
0.2 ng/ml, respectively (data not shown). At these doses of
LPS, preincubation of RAW264-HIV-LTR-LUC cells with 100
g/ml Hsp10 for 2 h significantly inhibited LPS-stimulated
luciferase activity by 	30–50% (Fig. 3A). Preincubation
periods below 30 min resulted in less reproducible inhibition
(data not shown).
To illustrate that the inhibitory activity of Hsp10 (Fig. 3A) was
lost after proteolytic degradation, Hsp10 was digested with tryp-
sin, and the trypsin activity was destroyed by heating (90 °C for
15 min) before the addition to the bioassays (see “Materials and
Methods”). Destruction of Hsp10 by trypsin was confirmed by
SDS-PAGE/Western blotting and the rhodanese refolding assay
(data not shown). (Heating alone failed to affect significant
Hsp10 activity in the LUC or the rhodanese refolding assays;
data not shown). Hsp10 pretreatment again significantly inhib-
ited LPS-mediated luciferase activity (Fig. 3B, Control versus
Hsp10, p  0.001, see the figure legend). However, trypsin/heat-
treated Hsp10 failed to inhibit LPS signaling (Fig. 3B, Trypsin
Hsp10), giving values similar to trypsin/heat-treated buffer con-
trols (Fig. 3B, Trypsin Buffer). As expected, trypsin treatment
(followed by heating at 90 °C for 15 min) failed to affect signifi-
cantly the activity of E. coli LPS (Fig. 3B, Trypsin LPS). Thus,
proteolytic degradation of Hsp10 resulted in the loss of inhibitory
activity by Hsp10 preparations, illustrating that trypsin-resis-
tant contaminants (e.g. LPS) of the Hsp10 preparations were not
responsible for the inhibitory activity.
Tolerance Induction Was Not Responsible for Inhibition of
LPS Signaling in RAW264-HIV-LTR-LUC Cells—LPS toler-
ance is a well recognized phenomenon whereby the response to
a second stimulus with LPS is reduced. LPS tolerance is nor-
mally induced if the time interval between the two LPS expo-
sures exceeds 3 h and the concentration of the LPS during the
initial exposure is sufficiently high to stimulate the macro-
phages (57, 58). To formally discount tolerance induction as
responsible for the observations in Fig. 3A, RAW264-HIV-LTR-
LUC cells were pretreated with a range of LPS concentrations
for 2 h followed by stimulation with 5, 1, and 0.2 ng/ml LPS.
Pretreatment with LPS concentrations ranging from 1 to
0.0005 ng/ml did not inhibit the induction of LUC activity by
the second LPS exposure (Fig. 3C). Thus, for the RAW264-HIV-
LTR-LUC system the 2-h pretreatment period appeared insuf-
ficient for tolerance induction. Furthermore, sub-stimulating
doses of LPS (0.005–0.0005 ng/ml), potentially similar to those
found in Hsp10 preparations, also failed to inhibit LPS-medi-
ated LUC activity. LPS tolerance was, therefore, not responsi-
ble for the observations in Fig. 3A since (i) the 2-h interval
between LPS exposures was insufficient for LPS tolerance in-
duction in the RAW264-HIV-LTR-LUC system, and (ii) unde-
tectable (or sub-stimulating) levels of LPS, which are poten-
tially contaminating the Hsp10 preparations, were unable to
mediate LPS tolerance.
Hsp10-mediated Reduction of LPS-stimulated LUC Activity
in RAW264-HIV-LTR-LUC Cells Was Dose-responsive—The re-
ductions in LUC activity shown in Fig. 3A were obtained using
100 g/ml Hsp10. To determine whether the activity of Hsp10
was dose-related, RAW264-HIV-LTR-LUC cells were treated
with a range of Hsp10 concentrations before the addition of
LPS (treatment with 100 g/ml, thus, represents a repeat of
the experiments shown in Fig. 3A). A clear dose response
emerged with increasing levels of inhibition apparent from 2 to
100 g of Hsp10, with the inhibition appearing to level off after
100 g/ml (Fig. 3D).
Hsp10 Reduced RANTES and IL-6 Production in LPS-stim-
ulated RAW264.7 Cells—To determine whether the Hsp10-
mediated reduction in NF-B activation seen in Fig. 3A also
affected LPS-induced pro-inflammatory mediator secretion,
the affect of Hsp10 on RANTES and IL-6 secretion levels by
RAW264.7 cells was investigated. An LPS dose of 1 ng was
used that induced 50% of maximal RANTES production in
this 6-h assay (data not shown). The 2-h preincubation period
(similar to that used above) was unable to induce tolerance in
these assays irrespective of the dose of LPS used (data not
shown). Hsp10 mediated a dose-related reduction in both LPS-
induced RANTES (Fig. 3E) and IL-6 (Fig. 3F) secretion, illus-
trating that inhibition of NF-B activation in this system leads
to reduction in pro-inflammatory mediator secretion.
Hsp10 Activity Was Independent of IL-10—To determine the
effect of Hsp10 on cells in vivo, mice were treated with Hsp10
followed by isolation of their peritoneal macrophages for stim-
ulation with LPS in vitro. LPS-induced secretion of TNF- from
the peritoneal macrophages was significantly lower in animals
that had been treated with Hsp10 (Fig. 4A), illustrating that
Hsp10 mediated similar effects on primary macrophages
treated in vivo as seen with RAW264.7 cells treated in vitro.
IL-10 is a potent immunosuppressive cytokine able to inhibit
TLR4 signaling (59, 60). When splenocytes from Hsp10-treated
animals were stimulated with 10 g/ml LPS (the minimum
dose that reliably induces detectable IL-10 in this system), a
significant increase in IL-10 production was observed com-
pared with buffer-treated animals (Fig. 4B). However, the
Hsp10-mediated reduction in LPS-induced TNF- production
(Fig. 4A) did not require IL-10, since similar reductions in
TNF- secretion were observed when peritoneal macrophages
from Hsp10-treated IL-10/ mice were stimulated with LPS
in vitro (Fig. 4C). Thus, reduced TNF- secretion and increased
IL-10 production appear to be independent consequences of
Hsp10 treatment.
Hsp10 Treatment and T Cell IFN- and IL-4 Secretion—Th1
immune responses are usually characterized by the production
of pro-inflammatory cytokines such as TNF- and IFN-,
whereas Th2 responses involve IL-4 and IL-10 secretion. Be-
cause Th2 responses are often able to suppress Th1 cytokine
production, the influence of Hsp10 on Th1/Th2 balance was
investigated. Mice were treated with Hsp10 as above, and the
splenocyte-derived T cell populations were stimulated in vitro
with allogeneic splenocytes for 7 days in a mixed lymphocyte
culture. After this Hsp10 treatment protocol, the proliferation
of T cells within the mixed lymphocyte cultures was not signif-
icantly different between Hsp10-treated and control animals
(data not shown). The resulting cultures were then stimulated
with plate-immobilized CD3/CD28 antibodies (to stimulate T
cells), and the culture supernatants were examined for cyto-
kines. Neither T cell IL-4 secretion (Fig. 4D) nor IFN- secre-
tion (Fig. 4E) differed significantly between Hsp10-treated and
control animals. Thus, at the Hsp10 dose and treatment regi-
mens used here, Hsp10 did not significantly influence the Th1/
Th2 profile. T cell IL-10 secretion was slightly but significantly
elevated (Fig. 4F), and a similar elevation in IL-10 secretion
could be observed when Hsp10 was added in vitro to a mixed
lymphocyte culture with the cells derived from untreated ani-
mals (data not shown). These data indicate that Hsp10 can
enhance IL-10 production in response to mixed lymphocyte
culture stimulation and suggest that the Hsp10-enhanced
IL-10 production seen above may arise in part from T cell-
derived IL-10.
Hsp10 Reduced LPS-induced TNF- and IL-6 Production in
Human Peripheral Blood Mononuclear Cells—To determine
whether Hsp10 is also active on primary human cells, PBMC
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FIG. 3. Hsp10 inhibited LPS-induced activation of NF-B activity in RAW264.7 cells. A, Hsp10-mediated inhibition of LPS-induced
NF-B activity. In nine separate experiments 100 g/ml Hsp10 (Hsp10) or buffer (Hsp10) was preincubated with RAW264-HIV-LTR-LUC cells
for 2 h. LPS was then added at 5, 1, or 0.2 ng/ml, and luciferase activity was measured after another 2-h incubation. The relative light units (RLU)
of luciferase obtained with 5 ng/ml LPS (in the absence of Hsp10) was set at 100% relative luciferase activity, and 0% represents the RLU obtained
in the absence of LPS. Hsp10, in the absence of LPS, did not stimulate significant luciferase activity (data not shown). The mean percentage
reduction (S.D.) in RLU mediated by Hsp10 is indicated for each concentration of LPS, and the significance was calculated using a paired t test.
B, trypsin-treated Hsp10 failed to inhibit LPS-induced NF-B activity. Treatment of RAW264-HIV-LTR-LUC cells in duplicate for 2 h with 100
g/ml Hsp10 (Hsp10) significantly reduced the RLU induced by LPS compared with cells treated with buffer (Control). Calculation of the percent
reductions in RLU after subtraction of background were 29.7  0.8 (S.D.), 50  4.6, and 71  7.7 for 5, 1, and 0.2 ng/ml, respectively (p  0.001
by two factor ANOVA, which included a term for LPS concentration). Compared with the control, treatment with trypsin-treated Hsp10 (Trypsin
Hsp10) gave 0.1  8.8, 11.6  4.2, and 21  7.4, and trypsin-treated buffer (Trypsin Buffer) gave 1.4  2.1, 5.8  1.1, and 14.9  2.4% reduction
for 5, 1, and 0.2 ng/ml LPS, respectively (neither was significantly different from control or each other). Trypsin treatment of the stimulating LPS
did not affect LPS activity (Trypsin LPS, p  0.05). C, LPS pretreatment 2 h before LPS stimulation did not inhibit LUC activity. RAW264-HIV-
LTR-LUC cells were pretreated with the indicated LPS concentrations in duplicate, after 2 h the cells were stimulated with 5, 1, 0.2, and 0 ng/ml
LPS, and the LUC activity was measured 2 h later. D, Hsp10-mediated reduction in LPS-induced LUC activity is dose-responsive. The experiment
was set up as in Fig. 3A, except the Hsp10 concentration was varied as indicated. For each LPS concentration the percent inhibition in LUC activity
over control cells not pretreated with Hsp10 is indicated. E and F, Hsp10-mediated inhibition of LPS-induced RANTES and IL-6 secretion.
RAW264.7 cells were incubated with the indicated Hsp10 concentration for 2 h followed by the addition of 1 ng/ml LPS. After 6 h triplicate
supernatants were analyzed for RANTES and IL-6 by ELISA. The mean percentage reduction in RANTES and IL-6 secretion mediated by 100
g/ml Hsp10 is indicated. Significance was calculated using a paired t test.
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from healthy donors were pretreated with Hsp10 or buffer for
1 h and then stimulated with 0.04 ng/ml LPS for 20 h. This dose
of LPS was established as the lowest dose reliably able to
stimulate significant TNF- secretion (Fig. 1) and corresponds
to the dose in humans that produces a mild transient syndrome
similar to clinical sepsis (61, 62). In PBMC from 8 donors, 1
g/ml Hsp10 mediated an average 23.7% reduction, and 10
g/ml mediated an average 23.3% reduction in LPS-induced
TNF- secretion (Fig. 5A), illustrating that Hsp10 also reduces
LPS-induced TNF- secretion from PBMC. No significant re-
duction in TNF- secretion was observed when 0.1 g/ml
Hsp10 was used (data not shown). To illustrate that tolerance
induction was not operating in this system, PBMC were pre-
treated with a range of LPS concentrations, and 1 h later they
were stimulated with 0.04 ng/ml LPS for 20 h. LPS pretreat-
ment for 1 h did not inhibit TNF- secretion stimulated by the
second LPS treatment (Fig. 5B), illustrating that LPS tolerance
does not account for the activity of Hsp10.
IL-6 is another well known inflammatory cytokine induced
by LPS (63). To determine whether Hsp10 inhibited LPS-in-
duced IL-6 secretion, PBMC from eight donors were treated
with 1 or 10 g/ml Hsp10 or buffer for 1 h followed by stimu-
lation with 0.04 ng/ml LPS for 20 h. An average 18.6 and 24.4%
reduction in LPS-induced IL-6 secretion was observed for 1 or
10 g/ml Hsp10, respectively (Fig. 5C). No significant reduction
in IL-6 secretion was observed when 0.1 g/ml Hsp10 was used
(data not shown). LPS pretreatment for 1 h did not inhibit IL-6
secretion stimulated by a second LPS treatment, again illus-
trating that tolerance induction was not operating in this sys-
tem (Fig. 5D).
Hsp10 Treatment Inhibited LPS-induced TNF- Secretion in
Vivo—A modified endotoxemia model was used to determine
whether Hsp10 delivered in vivo would reduce the levels of
pro-inflammatory mediators in serum after LPS challenge.
FIG. 4. Effect of Hsp10 on cytokine secretion in murine systems. A, Hsp10 treatment reduced the capacity of LPS-stimulated peritoneal
macrophages to produce TNF-. C57BL/6 mice (n  3 per group) were treated with Hsp10 (Hsp10) or buffer (Hsp10). Peritoneal macrophages
were harvested by peritoneal lavage on day 6 and pooled from individual animals within the treatment group. Cells were plated at 2 105 cells/well
in the presence of LPS (1 g/ml). Culture supernatants were collected at 5 h, and levels of TNF- were assessed by ELISA (wells without LPS
produced no detectable TNF-; data not shown). The mean  S.E. of triplicate wells are shown and are normalized to production per 105
macrophages based on CD11b staining. Data from two repeat experiments are shown, the average percentage reduction in TNF- ( S.D.) is
indicated, and the significance was calculated using a two way ANOVA, which takes account of the different experiments. B, Hsp10 treatment
augmented IL-10 production from splenocytes. C57BL/6 mice (n  3 per group) were treated with either Hsp10 or control diluent as above.
Splenocytes were harvested on day 6, pooled from individual animals within a treatment group, and cultured at 5  105 cells/well in the presence
of LPS (10 g/ml). Culture supernatants were collected at 48 h, and levels of IL-10 were determined by ELISA (wells without LPS produced no
detectable IL-10; data not shown). Means  S.E. of triplicate wells are shown. Average percentage increase is shown with statistics calculated as
for A. C, Hsp10 treatment reduced TNF- production from IL-10/ peritoneal macrophages. IL-10/ C57BL/6 mice (n  3) were treated with
Hsp10 (black bars) or control diluent (white bars) as above, and peritoneal macrophages were harvested as for A. After 5 h of culture in the presence
of LPS (0.1, 1, or 10 g/ml) TNF- was determined in culture supernatants by ELISA. The mean  S.E. of triplicate wells for one representative
experiment is shown. TNF- levels were compared for Hsp10-treated and control animals using a non-parametric t test. D–F, effect of Hsp10
treatment on T cell IL-4, IFN-, and IL-10 secretion. C57BL/6 mice were treated with Hsp10 as above. T cells (3  106 cells/well) from
Hsp10-treated and control animals were stimulated in culture for 7 days with irradiated allogeneic B6D2F1 splenocytes (5  106 cells/well). On
day 7 T cells were collected and plated in triplicate (105 CD3-positive cells/well) and re-stimulated with plate-bound antibodies to CD3 and CD28.
Culture supernatants were harvested at 24 h, and concentrations of IFN-, IL-4, and IL-10 were determined by ELISA. Results are the mean 
S.E. of triplicate wells from one representative experiment, and statistics were calculated as for C.
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BALB/c mice were given 100 g of intravenous Hsp10 30 min
before injection of 10 g of intravenous LPS, and blood was
removed after 1.5 h. The Hsp10 treatment provided an average
47.6% reduction in serum TNF- levels, an average 40.1%
reduction in serum RANTES, and an average 43.3% increase in
serum IL-10 levels in several repeat experiments (Fig. 6A).
These data are consistent with the tissue culture experiments
and illustrate the in vivo efficacy of Hsp10 in reducing pro-
inflammatory mediators and increasing IL-10 production after
challenge with LPS.
Hsp10 Reduced the Acute Symptoms of GVHD—Acute GVHD
after allogeneic bone marrow transplantation is a T cell-medi-
ated disease in which donor T cells recognize recipient allo-
antigens and differentiate in a Th1 dominant fashion. The
resulting T cell-derived Th1-cytokines (primarily IFN-) prime
donor mononuclear cells to release cytopathic quantities of
inflammatory cytokines (e.g. TNF-) when they are stimulated
with LPS that has leaked through the radiation-damaged gas-
trointestinal mucosa. These cytokines and the allo-reactive T
cells then contribute to increasing gastrointestinal damage and
LPS leakage. GVHDmortality in bone marrow transplantation
models is prevented if the donor mononuclear cells lack TLR4
(64), LPS is effectively blocked (by therapeutic antagonists)
(65), or TNF- itself is neutralized (51). The effect of Hsp10
administration during the peri-transplant period on GVHD
was, therefore, investigated.
Hsp10 treatment of transplant donors and recipient animals
before transplant significantly delayed GVHD mortality (Fig.
6B). In addition, the severity of GVHD as determined by the
clinical score was also significantly reduced on day 7 after the
bone marrow transplantation (Fig. 6B). Although Hsp10 treat-
ment delayed GVHD mortality and reduced early morbidity,
ultimately the animals succumbed to GVHD, consistent with
the inability of Hsp10 to neutralize completely TNF- secretion
or to affect IFN- secretion (Fig. 4, A and E). Treatment of
animals with Hsp10 post-transplant failed in isolation to ame-
liorate significantly GVHD (data not shown).
Hsp10 and Hsp60 in the Inhibition of LPS Signaling—In the
mitochondria Hsp10 binds to Hsp60 in the presence of ATP and
magnesium ions (1–3), and both ATP and magnesium ions are
also present in the extracellular fluids or medium (66). To
determine whether the inhibitory activity of Hsp10 on LPS is
influenced by Hsp60, RAW264-HIV-LTR-LUC cells were incu-
bated with polyclonal anti-Hsp60 antibodies before the addi-
tion of Hsp10 and LPS. Preincubation of RAW264-HIV-LTR-
LUC cells with anti-Hsp60 serum, but not control serum,
prevented the Hsp10-mediated reduction of LPS-induced
NF-B activation (Fig. 7), suggesting that Hsp60 may be re-
quired for Hsp10 activity. The anti-Hsp60 antibody by itself
mediated a similar level of inhibition of LPS signaling to that
seen for Hsp10 treatment (Fig. 7), indicating that anti-Hsp60
and Hsp10 individually mediate inhibitory activity of a similar
magnitude in this system. However, when added together there
was no additive inhibitory effect (the lack of detectable LUC
activity when cells were incubated with either antisera alone
illustrated that endotoxin contamination of the antibodies was
below the level of detection; see Fig. 1A).
DISCUSSION
In addition to its critical role in protein folding within the
mitochondria, Hsp10 appears to have an extracellular role in the
modulation of specific inflammatory processes. In a number of
different human and murine in vitro systems and in two murine
disease models, Hsp10 consistently inhibited LPS-induced secre-
tion of the pro-inflammatory cytokines TNF-, IL-6, and the
pro-inflammatory chemokine RANTES, and increased LPS-in-
duced secretion of the anti-inflammatory cytokine IL-10. The
Hsp10-mediated reduction in pro-inflammatory mediator secre-
tion was never absolute; instead, Hsp10 mediated a 20–50%
reduction in pro-inflammatory mediator levels, depending on the
system and the dose of LPS and Hsp10. Hsp10 increased LPS-
induced IL-10 secretion by 	30–200% depending on the system;
however, the reduction in TNF- secretion was not dependent on
this elevation of IL-10. We were unable to confirm previous
reports (40, 41) that anti-Hsp10 antibodies reduced the growth of
tumor cells in vitro or in vivo, nor were we able to demonstrate
that Hsp10 is a growth factor for tumor cells.
Given that E. coli-derived LPS is a well described agonist for
TLR4, the experiments described herein indicate that Hsp10
can reduce the magnitude of TLR4 signaling. The HIV LTR is
highly responsive to NF-B activation but whether Hsp10 also
modulates signaling via the other pathways stimulated by the
TLR4-complex remains to be established (13, 21). How Hsp10
mediates its inhibitory activity is unclear, although it appears
FIG. 5. Hsp10 treatment of human peripheral blood mononu-
clear cells reduced LPS-induced TNF- and IL-6 secretion. A,
Hsp10 reduced LPS-induced TNF- secretion. Hsp10 (1 and 10 g/ml)
or buffer (0) was added to PBMC from eight different donors 1 h before
the addition of 0.04 ng/ml LPS. Supernatants were removed after 20 h
and analyzed for TNF-. The percentage reductions and significance
calculated using a paired t test are indicated. For all donors 10 g/ml
Hsp10 in the absence of LPS failed to induce TNF- levels above the
level of detection (31 pg/ml) (data not shown). B, pretreatment with LPS
for 1 h was unable to induce tolerance to subsequent LPS-induced
TNF- secretion. PBMC were exposed to the indicated LPS pretreat-
ment concentrations. After 1 h the PBMC were stimulated with 0.04
ng/ml LPS, and the supernatants were analyzed for cytokine 20 h later.
C, Hsp10 reduced LPS-induced IL-6 secretion. Hsp10 (1 and 10 g/ml)
or buffer (0) was added to PBMC from eight different donors 1 h before
the addition of 0.04 ng/ml LPS. Supernatants were removed after 20 h
and analyzed for IL-6. The percentage reductions and significance (cal-
culated as for A) are indicated. For all donors 10 g/ml Hsp10 in the
absence of LPS failed to induce IL-6 levels above the level of detection
(9 pg/ml) (data not shown). D, pretreatment with LPS for 1 h was
unable to induce tolerance to subsequent LPS-induced IL-6 secretion.
PBMC were exposed to the indicated LPS pretreatment concentrations.
After 1 h the PBMC were stimulated with 0.04 ng/ml LPS, and the
supernatants were analyzed for cytokine 20 h later.
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to effect inhibition very rapidly, within 30 min (Fig. 6A) to 2 h
(Fig. 3A). This might implicate inhibition of early signaling
events or activation of rapid negative feedback mechanisms
such as phosphoinositide 3-kinase (28). However, we have been
unable to prevent Hsp10 activity with the specific phospho-
inositide 3-kinase inhibitor wortmannin (data not shown), sug-
gesting this pathway is not involved in the Hsp10 mechanism
of action.
FIG. 7. Hsp10 activity was blocked
by anti-Hsp60 serum. RAW264-HIV-
LTR-LUC cells were treated with anti-
Hsp60 or control serum for 1 h, and then
Hsp10 (100 g/ml) (Hsp10) or buffer
(Hsp10) was added for a further 2 h.
LPS was then added, and luciferase activ-
ity was measured 2 h later. The mean
percentage reduction (S.D.) in relative
light units is indicated for 5, 1, and 0.2
ng/ml LPS taken together, and the signif-
icance was calculated using a two way
ANOVA, which included a term for LPS
concentration.
FIG. 6. Hsp10 activity in murine in-
flammatory models. A, Hsp10 reduced
LPS-induced serum TNF- and RANTES
production and increased IL-10 levels. In
five separate experiments BALB/c mice
(n  3 or 4 per group) were given buffer
(Hsp10) or 100 g of Hsp10 (Hsp10)
intravenously 30 min before intravenous
administration of 10 g of LPS. After
1.5 h the animals were sacrificed, and
serum TNF-, RANTES, and IL-10 levels
were determined (the latter two were as-
sessed in 3/5 experiments). Error bars
represent S.E. within each experiment.
The percentage reduction in TNF- and
RANTES and increase in IL-10 (S.D.) is
indicated, and the significance was calcu-
lated using two way ANOVA, which took
into account the separate experiments.
No TNF- or RANTES was detected in
animals treated with Hsp10 alone (data
not shown). B, pretransplant treatment
with Hsp10 delayed GVHD mortality and
reduced clinical severity of acute disease.
Syngeneic negative controls (n 8) (white
circles) represent B6D2F1 mice trans-
planted with syngeneic B6D2F1 bone
marrow and T cells. Allogeneic positive
controls (n  10) (white squares) repre-
sent diluent pretreated B6D2F1 recipient
mice transplanted with cells from diluent
pretreated B6 donor mice. Allogeneic 
Hsp10 (n  10) (black squares) represent
B6D2F1 recipients receiving bone mar-
row and T cell grafts from B6 donor mice
where both recipients and donors were
pretreated with Hsp10 before transplan-
tation. Kaplan-Meier survival curves and
clinical scores are shown for the three
groups, and the allogeneic groups treated
with and without Hsp10 are compared by
Log Rank Statistic and non-parametric t
test, respectively. Clinical scores were
only significantly different on day 7.
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The reported association of extracellular Hsp60 with TLR4
signaling (13) and the known interaction between Hsp10 and
Hsp60 in the mitochondria suggested that Hsp10 might inhibit
LPS-induced TLR4 signaling by interacting with Hsp60 in the
extracellular milieu. This notion is supported by our finding that
Hsp10 activity is blocked andmimicked by anti-Hsp60 antibodies
(Fig. 7). Although Hsp60 was reported to stimulate TLR2 and
TLR4 signaling, recent reports (22, 67) and our own studies (data
not shown) indicate that such activity is likely due to LPS con-
tamination of Hsp60 preparations. Nevertheless, in agreement
with previous reports (24, 25), anti-Hsp60 antibodies were able to
inhibit LPS-mediated signaling (Fig. 7). Thus, rather than being
able by itself to stimulate TLR4, Hsp60 may be involved in
augmenting LPS-induced signaling (7, 13, 68). A potentially sim-
ilar role in the augmentation of inflammatory responses has been
proposed for Hsp70 and Hsp90 (21, 69–71). Thus, Hsp10 may
inhibit TLR4 signaling by inhibiting Hsp60-mediated augmenta-
tion of TLR4 signaling. Hsp60 is also reported to contribute to
TLR2 signaling (19, 72), and we have recently shown that Hsp10
can also inhibit signaling by a TLR2 agonist, whereas Hsp10 was
ineffective in inhibiting TLR9 signaling (data not shown). This
line of reasoning might lead one to speculate that the physiolog-
ical role of circulating Hsp10 during early pregnancy (38) may be
to remove the Hsp60 danger signal (15) that has arisen from
pregnancy (73, 74) rather than from pathogen-induced tissue
damage. We are currently in the process of seeking formal proof
of Hsp10 binding to extracellular Hsp60, as it remains possible
that Hsp10 binds to an alternative receptor (75) and that Hsp10
and anti-Hsp60 exert similar suppressive (but non-additive) ef-
fects on TLR4 signaling (Fig. 7) but use distinct pathways.
The ability to reduce but not completely suppress TNF-
secretion would distinguish Hsp10 from other anti-inflamma-
tory therapies, particularly those based on anti-TNF- antibod-
ies, which can accomplish efficient removal of TNF-. However,
such removal may not always be desirable (76). For instance,
anti-TNF- antibody treatment has been shown ultimately to
increase the severity of multiple sclerosis (77). Multiple sclero-
sis has been suggested as a possible therapeutic target for
Hsp10 since Hsp10 is reported to reduce clinical signs and
delay onset of disease in a murine model of multiple sclerosis
(experimental autoimmune encephalomyelitis) (35). The ability
of Hsp10 to reduce the expression of inflammatory mediators
indicates that Hsp10 may find therapeutic application in con-
ditions where excessive LPS, TLR4 (and/or TLR2) signaling,
and/or Hsp60 leads to pathology (11, 12, 21).
Acknowledgments—We thank Steve Mahler, Dave Chin, and Chris
Marquis (Bioengineering Centre, University of New South Wales) for
the production of recombinant Hsp10.
REFERENCES
1. Fiaux, J., Bertelsen, E. B., Horwich, A. L., andWuthrich, K. (2002)Nature 418,
207–211
2. Meyer, A. S., Gillespie, J. R., Walther, D., Millet, I. S., Doniach, S., and
Frydman, J. (2003) Cell 113, 369–381
3. Xu, Z., Horwich, A. L., and Sigler, P. B. (1997) Nature 388, 741–750
4. Belles, C., Kuhl, A., Nosheny, R., and Carding, S. R. (1999) Infect. Immun. 67,
4191–4200
5. Feng, H., Zeng, Y., Whitesell, L., and Katsanis, E. (2001) Blood 97, 3505–3512
6. Shin, B. K., Wang, H., Yim, A. M., Le Naour, F., Brichory, F., Jang, J. H., Zhao,
R., Puravs, E., Tra, J., Michael, C. W., Misek, D. E., and Hanash, S. M.
(2003) J. Biol. Chem. 278, 7607–7616
7. Barazi, H. O., Zhou, L., Templeton, N. S., Krutzsch, H. C., and Roberts, D. D.
(2002) Cancer Res. 62, 1541–1548
8. Kaur, I., Voss, S. D., Gupta, R. S., Schell, K., Fisch, P., and Sondel, P. M. (1993)
J. Immunol. 150, 2046–2055
9. Soltys, B. J., and Gupta, R. S. (1997) Cell Biol. Int. 21, 315–320
10. Laad, A. D., Thomas, M. L., Fakih, A. R., and Chiplunkar, S. V. (1999) Int. J.
Cancer 80, 709–714
11. Xu, Q. (2003) Curr. Opin. Cardiol. 18, 245–252
12. Lewthwaite, J., Owen, N., Coates, A., Henderson, B., and Steptoe, A. (2002)
Circulation 106, 196–201
13. Johnson, G. B., Brunn, G. J., and Platt, J. L. (2003) Crit. Rev. Immunol. 23,
15–44
14. Flohe, S. B., Bruggemann, J., Lendemans, S., Nikulina, M., Meierhoff, G.,
Flohe, S., and Kolb, H. (2003) J. Immunol. 170, 2340–2348
15. Wallin, R. P., Lundqvist, A., More, S. H., Von Bonin, A., Kiessling, R., and
Ljunggren, H. G. (2002) Trends Immunol. 23, 130–135
16. Beg, A. A. (2002) Trends Immunol. 23, 509–512
17. Kligman, I., Grifo, J. A., and Witkin, S. S. (1996) Hum. Reprod. 11, 2736–2738
18. Ueki, K., Tabeta, K., Yoshie, H., and Yamazaki, K. (2002) Clin. Exp. Immunol.
127, 72–77
19. Zanin-Zhorov, A., Nussbaum, G., Franitza, S., Cohen, I. R., and Lider, O.
(2003) FASEB J. 17, 1567–1569
20. Triantafilou, M., and Triantafilou, K. (2002) Trends Immunol. 23, 301–304
21. Triantafilou, M., and Triantafilou, K. (2004) Expert Rev. Mol. Med. 2004, 1–18
22. Gao, B., and Tsan, M. F. (2004) Biochem. Biophys. Res. Commun. 317,
1149–1154
23. Tsan, M. F., and Gao, B. (2004) Am. J. Physiol. Cell Physiol. 286, C739–C744
24. Bulut, Y., Faure, E., Thomas, L., Karahashi, H., Michelsen, K. S., Equils, O.,
Morrison, S. G., Morrison, R. P., and Arditi, M. (2002) J. Immunol. 168,
1435–1440
25. Retzlaff, C., Yamamoto, Y., Hoffman, P. S., Friedman, H., and Klein, T. W.
(1994) Infect. Immun. 62, 5689–5693
26. Doyle, S., Vaidya, S., O’Connell, R., Dadgostar, H., Dempsey, P., Wu, T., Rao,
G., Sun, R., Haberland, M., Modlin, R., and Cheng, G. (2002) Immunity 17,
251–263
27. Jones, B. W., Means, T. K., Heldwein, K. A., Keen, M. A., Hill, P. J., Belisle,
J. T., and Fenton, M. J. (2001) J. Leukocyte Biol. 69, 1036–1044
28. Fukao, T., and Koyasu, S. (2003) Trends Immunol. 24, 358–363
29. Lee, T. S., and Chau, L. Y. (2002) Nat. Med. 8, 240–246
30. Elenkov, I. J., and Chrousos, G. P. (2002) Ann. N. Y. Acad. Sci. 966, 290–303
31. Asadullah, K., Sterry, W., and Volk, H. D. (2003) Pharmacol. Rev. 55, 241–269
32. Kumar, S., Boehm, J., and Lee, J. C. (2003) Nat. Rev. Drug Discov. 2, 717–726
33. Zingarelli, B., Sheehan, M., and Wong, H. R. (2003) Crit. Care Med. 31, Suppl.
1, S105–S111
34. Rossi, A., Kapahi, P., Natoli, G., Takahashi, T., Chen, Y., Karin, M., and
Santoro, M. G. (2000) Nature 403, 103–108
35. Zhang, B., Walsh, M. D., Nguyen, K. B., Hillyard, N. C., Cavanagh, A. C.,
McCombe, P. A., and Morton, H. (2003) J. Neurol. Sci. 212, 37–46
36. Morton, H., McKay, D. A., Murphy, R. M., Somodevilla-Torres, M. J., Swanson,
C. E., Cassady, A. I., Summers, K. M., and Cavanagh, A. C. (2000) Immunol.
Cell Biol. 78, 603–607
37. Morton, H., Cavanagh, A. C., Athanasas-Platsis, S., Quinn, K. A., and Rolfe,
B. E. (1992) Reprod. Fertil. Dev. 4, 411–422
38. Morton, H. (1998) Immunol. Cell Biol. 76, 483–496
39. Cavanagh, A. C. (1996) Rev. Reprod. 1, 28–32
40. Quinn, K. A., Athanasas-Platsis, S., Wong, T. Y., Rolfe, B. E., Cavanagh, A. C.,
and Morton, H. (1990) Clin. Exp. Immunol. 80, 100–108
41. Quinn, K. A., and Morton, H. (1992) Cancer Immunol. Immunother. 34,
265–271
42. Sweet, M. J., and Hume, D. A. (1995) J. Inflamm. 45, 126–135
43. Mateo, L., La Linn, M., McColl, S. R., Cross, S., Gardner, J., and Suhrbier, A.
(2000) Intervirology 43, 55–60
44. Ryan, M. T., Naylor, D. J., Hoogenraad, N. J., and Hoj, P. B. (1995) J. Biol.
Chem. 270, 22037–22043
45. Brinker, A., Pfeifer, G., Kerner, M. J., Naylor, D. J., Hartl, F. U., and Hayer-
Hartl, M. (2001) Cell 107, 223–233
46. Linn, M. L., Bellett, A. J., Parsons, P. G., and Suhrbier, A. (1995) J. Virol.
Methods 52, 51–54
47. Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D.,
Warren, J. T., Bokesch, H., Kenney, S., and Boyd, M. R. (1990) J. Natl.
Cancer Inst. 82, 1107–1112
48. Anraku, I., Harvey, T. J., Linedale, R., Gardner, J., Harrich, D., Suhrbier, A.,
and Khromykh, A. A. (2002) J. Virol. 76, 3791–3799
49. MacDonald, K. P., Rowe, V., Filippich, C., Thomas, R., Clouston, A. D., Welply,
J. K., Hart, D. N., Ferrara, J. L., and Hill, G. R. (2003) Blood 101,
2033–2042
50. Morse, H. C., III, Shen, F. W., and Hammerling, U. (1987) Immunogenetics 25,
71–78
51. Hill, G. R., Crawford, J. M., Cooke, K. R., Brinson, Y. S., Pan, L., and Ferrara,
J. L. (1997) Blood 90, 3204–3213
52. Hill, G. R., Cooke, K. R., Teshima, T., Crawford, J. M., Keith, J. C., Jr.,
Brinson, Y. S., Bungard, D., and Ferrara, J. L. (1998) J. Clin. Investig. 102,
115–123
53. Hill, G. R., Teshima, T., Gerbitz, A., Pan, L., Cooke, K. R., Brinson, Y. S.,
Crawford, J. M., and Ferrara, J. L. (1999) J. Clin. Investig. 104, 459–467
54. Cooke, K. R., Kobzik, L., Martin, T. R., Brewer, J., Delmonte, J., Jr., Crawford,
J. M., and Ferrara, J. L. (1996) Blood 88, 3230–3239
55. Yamamoto, A., Ochiai, M., Kataoka, M., Toyoizumi, H., and Horiuchi, Y. (2002)
Biologicals 30, 85–92
56. Gearing, A. J., Leung, H., Bird, C. R., and Thorpe, R. (1989) Hybridoma 8,
361–367
57. West, M. A., and Heagy, W. (2002) Crit. Care Med. 30, Suppl. 1, S64–S73
58. Fujihara, M., Muroi, M., Tanamoto, K., Suzuki, T., Azuma, H., and Ikeda, H.
(2003) Pharmacol. Ther. 100, 171–194
59. Berlato, C., Cassatella, M. A., Kinjyo, I., Gatto, L., Yoshimura, A., and Bazzoni,
F. (2002) J. Immunol. 168, 6404–6411
60. Suhrbier, A., and Linn, M. L. (2003) Trends Immunol. 24, 165–168
61. Granowitz, E. V., Porat, R., Mier, J. W., Orencole, S. F., Kaplanski, G., Lynch,
E. A., Ye, K., Vannier, E., Wolff, S. M., and Dinarello, C. A. (1993) J. Im-
munol. 151, 1637–1645
62. Lynn, M., Rossignol, D. P., Wheeler, J. L., Kao, R. J., Perdomo, C. A., Noveck,
R., Vargas, R., D’Angelo, T., Gotzkowsky, S., and McMahon, F. G. (2003)
J. Infect. Dis. 187, 631–639
Hsp10 Inhibits LPS-induced Inflammatory Mediator Production4046
 at UQ Library on October 19, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
63. Kanda, T., and Takahashi, T. (2004) Jpn. Heart J. 45, 183–193
64. Cooke, K. R., Hill, G. R., Gerbitz, A., Kobzik, L., Martin, T. R., Crawford, J. M.,
Brewer, J. P., and Ferrara, J. L. (2000) J. Immunol. 165, 6612–6619
65. Cooke, K. R., Gerbitz, A., Crawford, J. M., Teshima, T., Hill, G. R., Tesolin, A.,
Rossignol, D. P., and Ferrara, J. L. (2001) J. Clin. Investig. 107, 1581–1589
66. Beigi, R. D., and Dubyak, G. R. (2000) J. Immunol. 165, 7189–7198
67. Gao, B., and Tsan, M. F. (2003) J. Biol. Chem. 278, 22523–22529
68. Habich, C., Kempe, K., Van Der Zee, R., Burkart, V., and Kolb, H. (2003) FEBS
Lett. 533, 105–109
69. Triantafilou, M., and Triantafilou, K. (2004) Biochem. Soc. Trans. 32, 636–639
70. Moseley, P. (2000) Immunopharmacology 48, 299–302
71. Iwamoto, G. K., Ainsworth, A. M., and Moseley, P. L. (1999) Am. J. Physiol.
277, L1051–L1056
72. Kirschning, C. J., and Schumann, R. R. (2002) Curr. Top. Microbiol. Immunol.
270, 121–144
73. Kligman, I., Jeremias, J., Rosenwaks, Z., and Witkin, S. S. (1998) Am. J.
Reprod. Immunol. 40, 32–36
74. Ziegert, M., Witkin, S. S., Sziller, I., Alexander, H., Brylla, E., and Hartig, W.
(1999) Infect. Dis. Obstet. Gynecol. 7, 180–185
75. Athanasas-Platsis, S., Somodevilla-Torres, M. J., Morton, H., and Cavanagh,
A. C. (2004) Immunol. Cell Biol. 82, 361–369
76. Derksen, R. H., and Bijlsma, J. W. (2002) Ned. Tijdschr. Geneeskd. 146,
1165–1168
77. Wiendl, H., and Hohlfeld, R. (2002) BioDrugs 16, 183–200
Hsp10 Inhibits LPS-induced Inflammatory Mediator Production 4047
 at UQ Library on October 19, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Andreas Suhrbier
Howard, Flor de Maria Leon Flores, Daina Vanags, Dean J. Naylor, Geoffrey R. Hill and 
Barbara J. Johnson, Thuy T. T. Le, Caroline A. Dobbin, Tatjana Banovic, Christopher B.
Production
Heat Shock Protein 10 Inhibits Lipopolysaccharide-induced Inflammatory Mediator
doi: 10.1074/jbc.M411569200 originally published online November 16, 2004
2005, 280:4037-4047.J. Biol. Chem. 
  
 10.1074/jbc.M411569200Access the most updated version of this article at doi: 
 Alerts: 
  
 When a correction for this article is posted•  
 When this article is cited•  
 to choose from all of JBC's e-mail alertsClick here
  
 http://www.jbc.org/content/280/6/4037.full.html#ref-list-1
This article cites 75 references, 27 of which can be accessed free at
 at UQ Library on October 19, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
